Global Blood Therapeutics – Consensus Indicates Potential 98.2% Upside

Broker Ratings

Global Blood Therapeutics with ticker code (GBT) have now 18 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 152 and 45 with the average target price sitting at 95.5. With the stocks previous close at 48.18 this would imply there is a potential upside of 98.2%. The 50 day moving average now sits at 49.75 and the 200 moving average now moves to 60.63. The market cap for the company is $2,767m. Visit the company website at:

Global Blood Therapeutics, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, Oxbryta (voxelotor) tablets, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating Oxbryta that has completed Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. The company has a license and collaboration agreement with Syros Pharmaceuticals to discover, develop, and commercialize therapies for SCD) and beta thalassemia. Global Blood Therapeutics was founded in 2011 and is headquartered in South San Francisco, California.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits
You might also enjoy reading  Global Blood Therapeutics - Consensus Indicates Potential -5.8% Downside
Find more news, interviews, share price & company profile here for:

    Good news travels fast (but only if you make that happen). Share on:


      AIM All Share Index